Over the past year or so, the spotlight has been fixed on AAV as a promising opportunity for advancing gene therapy manufacture, but what challenges surround the manufacture of AAV, and how can novel technologies overcome these obstacles? Phacilitate Editor, Georgi Makin, explores this by putting ‘TESSA™ technology’ from OXGENE, a WuXi Advanced Therapies’ company, in the spotlight.
When it comes to manufacturing viral vectors, there remain a few challenges to be overcome to allow companies to produce batches large enough to satisfy clinical demand.
Up to now, plasmids have been the ‘gold standard’ for viral vector manufacture, providing robust manufacture of AAV for gene therapies currently in the pipeline. Plasmid engineering and robust transient manufacturing platforms have helped to ensure the success of AAV-based therapies so far but are not without their limitations.